NervGen Pharma Corp (V:NGEN) — Stock Price
NervGen Pharma Corp (V:NGEN) is currently trading at CA$5.15 CAD, up 0.00% today. Over the past 52 weeks, shares have ranged between CA$2.79 and CA$8.08. This page tracks NervGen Pharma Corp's live share price on the V exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NGEN stock market capitalisation.
NervGen Pharma Corp (NGEN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks NervGen Pharma Corp's daily closing share price and trading volume on the V exchange over the past year, giving a clear view of recent price momentum and liquidity.
NervGen Pharma Corp Income Statement — Revenue, Profit & Earnings by Year
NervGen Pharma Corp's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 |
| Cost of Revenue | — | — | CA$115.11K | CA$42.63K | CA$39.65K |
| Gross Profit | — | — | CA$-115.11K | CA$-42.63K | CA$-39.65K |
| Research & Development | CA$15.73 Million | CA$8.05 Million | CA$16.61 Million | CA$6.87 Million | CA$6.16 Million |
| SG&A | CA$9.18 Million | CA$9.63 Million | CA$6.34 Million | CA$5.94 Million | CA$5.03 Million |
| Total Operating Expenses | CA$24.93 Million | CA$17.78 Million | CA$23.03 Million | CA$12.81 Million | CA$11.20 Million |
| Operating Income | CA$-24.93 Million | CA$-17.78 Million | CA$-22.82 Million | CA$-12.87 Million | CA$-11.19 Million |
| EBITDA | — | — | CA$-22.71 Million | CA$-12.82 Million | CA$-11.15 Million |
| EBIT | — | — | CA$-22.82 Million | CA$-12.87 Million | CA$-11.19 Million |
| Interest Expense | — | CA$0.00 | CA$514.60K | CA$0.00 | CA$0.00 |
| Income Before Tax | CA$-24.01 Million | CA$-22.38 Million | CA$-20.72 Million | CA$-12.73 Million | CA$-11.19 Million |
| Income Tax Expense | — | — | CA$-2.62 Million | CA$-84.65K | CA$-9.74K |
| Net Income | CA$-24.01 Million | CA$-22.38 Million | CA$-18.11 Million | CA$-12.64 Million | CA$-11.18 Million |
NervGen Pharma Corp Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes NervGen Pharma Corp's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CA$19.49 Million | CA$13.24 Million | CA$23.88 Million | CA$17.90 Million | CA$6.68 Million |
| Total Current Assets | CA$19.01 Million | CA$12.52 Million | CA$23.15 Million | CA$17.42 Million | CA$6.20 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CA$97.23K | CA$0.00 | — | — | — |
| Net Receivables | — | CA$250.21K | CA$27.03K | CA$64.00K | CA$62.59K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | CA$295.28K | CA$2.69K | CA$2.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CA$16.91 Million | CA$15.25 Million | CA$10.41 Million | CA$1.08 Million | CA$755.07K |
| Total Current Liabilities | CA$16.90 Million | CA$15.14 Million | CA$10.22 Million | CA$1.08 Million | CA$755.07K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | CA$-22.17 Million | CA$-16.93 Million | CA$-5.60 Million |
| Total Stockholder Equity | CA$2.58 Million | CA$-2.01 Million | CA$13.46 Million | CA$16.82 Million | CA$5.92 Million |
| Retained Earnings | CA$-102.16 Million | CA$-78.15 Million | CA$-55.77 Million | CA$-35.05 Million | CA$-22.32 Million |
NervGen Pharma Corp Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how NervGen Pharma Corp generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-16.84 Million | CA$-11.30 Million | CA$-17.78 Million | CA$-8.27 Million | CA$-6.31 Million |
| Capital Expenditures | CA$0.00 | CA$141.40K | CA$21.11K | CA$45.09K | CA$3.42K |
| Free Cash Flow | CA$-16.84 Million | CA$-11.44 Million | CA$-17.81 Million | CA$-8.31 Million | CA$-6.31 Million |
| Investing Cash Flow | — | — | CA$-21.11K | CA$-45.09K | CA$-3.42K |
| Financing Cash Flow | CA$22.70 Million | CA$766.28K | CA$22.64 Million | CA$19.61 Million | CA$7.85 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CA$5.80 Million | CA$6.04 Million | CA$2.77 Million | CA$4.02 Million | CA$3.42 Million |
| Depreciation | CA$83.80K | CA$145.00K | CA$115.11K | CA$42.63K | CA$39.65K |
| Change in Cash | CA$5.61 Million | CA$-10.79 Million | CA$5.52 Million | CA$11.33 Million | CA$1.49 Million |
NervGen Pharma Corp Earnings History — EPS Actual vs. Analyst Estimates
Track NervGen Pharma Corp's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 02, 2026 | — | -0.06 | — |
| Nov 24, 2025 | -0.06 | -0.06 | +0.00% |
| Aug 26, 2025 | -0.13 | -0.07 | -85.71% |
| May 15, 2025 | -0.06 | -0.07 | +14.29% |
| Dec 31, 2024 | -0.14 | -0.10 | -40.00% |
| Nov 14, 2024 | -0.07 | -0.09 | +22.22% |
| Aug 22, 2024 | -0.11 | -0.09 | -22.22% |
| May 16, 2024 | -0.04 | -0.07 | +42.86% |